Jefferies Group’s Amicus Therapeutics FOLD Stock Holding History

Jefferies Group’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-25,500	Closed	-$252K	–	1771
2021 Q1	$252K	Sell	25,500 -20,000	-44%	-$310K	﹤0.01%	1294
2020 Q4	$1.05M	Buy	45,500 +20,000	+78%	+$409K	0.01%	930
2020 Q3	$360K	Buy	+25,500	New	+$372K	﹤0.01%	1063
2018 Q3	–	Sell	-1,300	Closed	-$20K	–	2504
2018 Q2	$20K	Buy	+1,300	New	+$19.7K	﹤0.01%	2239
2017 Q3	–	Sell	-19,300	Closed	-$194K	–	2432
2017 Q2	$194K	Hold	19,300	–	–	﹤0.01%	2045
2017 Q1	$138K	Buy	+19,300	New	+$122K	﹤0.01%	2098
2016 Q2	–	Sell	-17,300	Closed	-$146K	–	2221
2016 Q1	$146K	Buy	+17,300	New	+$123K	﹤0.01%	1912

Other funds holding FOLD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Jefferies Group's FOLD Position: Q4 2021 in Review

Jefferies Group sold out of Amicus Therapeutics (FOLD) in Q4 2021, closing a stake of 25,829 shares — an estimated $247K sold.

Jefferies Group first reported a position in FOLD in Q3 2014 and held it in 13 quarters. The position peaked at $729K in Q2 2019. 223 funds tracked by Wall St. Rank hold FOLD as of Q4 2021.

Jefferies Group reported no remaining Amicus Therapeutics position as of Q4 2021 after selling out during the quarter.
Jefferies Group sold 25,829 Amicus Therapeutics shares in Q4 2021, an estimated $247K.
Jefferies Group first reported a position in Amicus Therapeutics in Q3 2014 and held it in 13 quarters.
Jefferies Group's Amicus Therapeutics position peaked at $729K in Q2 2019.
223 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2021.

Based on Jefferies Group's 13F filing for Q4 2021, filed 14 Feb 2022.